Archives
-
CGP 55845 Hydrochloride for Reliable Assays
2026-09-26
Learn how CGP 55845 hydrochloride (SKU B5086) can help researchers isolate GABAB receptor-dependent effects in neurotransmission and cell-based experiments. This scenario-driven guide covers assay design, concentration interpretation, solution handling, and the limits of applying a receptor antagonist to viability readouts.
-
Prestained Protein Marker: F4005 Workflow Guide
2026-09-25
Practical guidance for interpreting protein blots alongside cell viability, proliferation, and cytotoxicity assays. Learn how APExBIO SKU F4005 supports size verification and workflow compatibility without confusing a protein marker with a direct measure of cell viability.
-
Angiotensin I/II (1-5): RAS Workflow Guide
2026-09-25
Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for experiments examining renin-angiotensin system activity and related cardiovascular or renal endpoints. Use it in an established RAS workflow with appropriate vehicle controls; it is not a general-purpose peptide for unrelated signaling studies, and the product dossier does not specify assay concentrations or potency.
-
AmpliFold Capture-and-Release Boosts LFA Sensitivity
2026-09-24
The AmpliFold strategy uses a cleavable capture step followed by release and high-affinity rebinding to address kinetic limits in lateral flow assays. In a HER2 model, it improved sensitivity by up to 16-fold in selected configurations, including detection with large nanoparticles in buffer and human serum.
-
Capecitabine Assays: Activation or Resistance?
2026-09-24
Capecitabine response in a tumor model can reflect both cellular sensitivity and the model’s capacity to activate this prodrug. This article connects capecitabine pharmacology with patient-derived gastric cancer assembloid findings to help researchers distinguish those effects when designing preclinical assays.
-
CCT007093: A PPM1D Inhibitor for P38 Studies
2026-09-23
Use CCT007093 to test how PPM1D/WIP1 restrains P38 signaling, from renal tubular pyroptosis models to cancer-cell assays. Its value is strongest in a controlled workflow that pairs pathway readouts with viability, genetic, and inhibitor-rescue controls.
-
FDA Library Screening Finds Four MERS-CoV Inhibitors
2026-09-23
De Wilde and colleagues screened an FDA-approved compound library and identified chloroquine, chlorpromazine, loperamide, and lopinavir as low-micromolar inhibitors of MERS-CoV replication in cell culture. The study established a practical repurposing framework, while also showing why cellular activity must be followed by exposure, mechanism, animal, and clinical validation.
-
Interpreting In Vitro Cancer Drug Responses
2026-09-22
Hannah Schwartz’s dissertation distinguishes relative viability from fractional viability, showing that growth inhibition and cell death are related but non-equivalent drug-response phenotypes. This framework improves assay design, time-course interpretation, and evaluation of anti-cancer compounds in cancer research.
-
Rice 5hmC Maps Reveal Context-Dependent Drought Control
2026-09-22
A 2025 rice study combines ACE-seq with optimized Tn5mC-seq to produce a single-base map of 5-hydroxymethylcytosine during drought and rehydration. Its findings show that 5hmC is a low-abundance, dynamic mark whose effect on transcription depends on whether it occurs in promoters, gene bodies, or other genomic compartments.
-
Capecitabine and the Tumor–Stroma Response
2026-09-21
Capecitabine offers translational researchers more than a fluoropyrimidine prodrug: its activation biology can expose how tumor–stroma interactions reshape chemotherapy response. Patient-derived gastric assembloids provide a practical framework for testing that hypothesis.
-
HotStart 2X Green qPCR Master Mix for Epigenetics
2026-09-21
Discover how HotStart 2X Green qPCR Master Mix can support targeted validation of RNA-seq findings in histone-acetylation and spermatogenesis research. This article connects assay chemistry with biological interpretation, helping researchers distinguish transcript changes from altered cell composition and protein-level phenotypes.
-
Proximity Labeling Tracks Synaptic Protein Trafficking
2026-09-20
Pascual-Caro and de Juan-Sanz developed a synaptic-cleft proximity-labeling strategy that captures endogenous proteins transiently exposed during synaptic vesicle exocytosis. By matching the biotinylation pulse to rapid vesicle cycling, the method enables activity-dependent proteomic analysis and provides direct evidence for trafficking of ATG9A and NPTX1.
-
NET-DNA–CCDC25 Control of ILC3 Repair
2026-09-19
A 2026 FASEB Journal study identifies a mechanistic link between neutrophil extracellular trap DNA, CCDC25 signaling in ILC3s, and impaired intestinal epithelial repair in ulcerative colitis models. Its combination of genetic, enzymatic, cellular, and epithelial-barrier experiments suggests that NET-DNA-driven suppression of IL-22 is an important contributor to mucosal injury.
-
Biotin-HPDP for S-Nitrosylation Assays
2026-09-18
Biotin-HPDP enables reversible thiol-specific protein labeling for investigating S-nitrosylation. This article develops an assay-design framework around STOP1 and STAR1 regulation during Arabidopsis aluminum stress, emphasizing controls, interpretation, and reversible enrichment.
-
TGF-β, Sca-1, and Mammary Cell Plasticity
2026-09-18
The reference study shows that TGF-β signaling dynamically regulates Sca-1 expression, lineage plasticity, and tumor-initiating behavior in pre-neoplastic and mammary cancer cell models. Its combination of comparative cell systems, pathway perturbation, and functional analysis clarifies why Sca-1 should be interpreted as a state-dependent marker rather than a fixed definition of stemness.